Exercise as a Preventive Agent to Combat Immobility in Patients with Ovarian or Endometrial Cancers Receiving Chemotherapy

The purpose of this research is to determine whether a 16-week virtually supervised
aerobic and resistance exercise program is feasible in patients receiving first-line
chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower
extremity function (function of the legs), lessen chemotherapy-induced peripheral
neuropathy (CIPN; numbness or tingling in the hands or feet), and if there is any effect
on inflammatory blood markers (the level of a certain marker in the blood that is
associated with inflammation; redness and swelling).

Inclusion Criteria:

- Newly diagnosed patients with stages III-IV ovarian or endometrial cancer

- Receiving first-line carboplatin and paclitaxel chemotherapy after surgery

- ≥18 years, children under the age of 18 will be excluded due to rarity of disease

- Physician's clearance to participate in moderate-vigorous intensity exercise

- Able to read, write, and understand English

- Ability to understand and the willingness to sign an informed consent document

- Willing to undergo two venous blood draws for the study

Exclusion Criteria:

- Pre-existing musculoskeletal, neurological, or cardiorespiratory conditions, as
determined by the treating oncologist

- Participants with uncontrolled intercurrent illness, as determined by the treating
oncologist

- Participants with psychiatric illness/social situations that would limit compliance
with study requirements, as determined by the treating oncologist

- Participants who have received prior chemotherapy for cancer treatment (e.g. taxanes
for breast cancer)